Official websites use. Share sensitive information only on official, secure websites. Another author, Rafael Zegarra-Parodi is an osteopathic practitioner in Paris and works in a private practice: Cabinet Victor Hugo, 7 rue Georges Ville, Paris France , without any conflict of interest with this article. He is also a Research Assistant Professor, A. Analyzed the data: EP IB. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
Pain is a common complication in patients with cystic fibrosis CF and is associated with shorter survival. A pilot multicenter randomized controlled trial was conducted with three parallel arms: OMT group A, 16 patients , sham OMT sham treatment, group B, 8 patients and no treatment group C, 8 patients.
Pain was rated as a composite of its intensity and duration over the previous month. The evolution of cervical pain, headache and quality of life QOL were similarly evaluated.
Cervical pain, headache and QOL scores did not differ between the treatment and control groups. This pilot study demonstrated the feasibility of evaluating the efficacy of OMT to treat the pain of patients with CF.
The lack of difference between the group treated with OMT and the control group may be due to the small number of patients included in this trial, which also precludes any definitive conclusion about the greater decrease of pain in patients receiving OMT or sham OMT than in those with no intervention. Cystic Fibrosis CF is an inherited multi systemic autosomal recessive disease with high morbidity and mortality, involving primarily the lungs and gastrointestinal tract [1].
